Predictors of Cognitive Improvement during 12 Weeks of Antidepressant Treatment in Patients with Major Depressive Disorder

키워드

참고문헌 (34)

1. Kessler RC, "The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)", Jama, 289, pp.3095~3105 (2003)
2. Moussavi S, "Depression, chronic diseases, and decrements in health: results from the world health surveys", Lancet, 370, pp.851~858 (2007)
3. Stewart WF, "Cost of lost productive work time among US workers with depression", JAMA, 289, pp.3135~3144 (2003)
4. American Psychiatry Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
5. Judd LL, "Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse", J Affect Disord, 50, pp.97~108 (1998)
6. Jaeger J, "Neurocognitive deficits and disability in major depressive disorder", Psychiatry Res, 145, pp.39~48 (2006)
7. 우영섭, "Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients", Clinical Psychopharmacology and Neuroscience, 14(1), pp.1~16 (2016), 대한정신약물학회
8. 김혜금, "Association between Cerebral Amyloid Deposition and Clinical Factors Including Cognitive Function in Geriatric Depression: Pilot Study Using Amyloid Positron Emission Tomography", Clinical Psychopharmacology and Neuroscience, 14(4), pp.378~382 (2016), 대한정신약물학회
9. Danner M, "Integrating patients' views into health technology assessment: analytic hierarchy process (AHP) as a method to elicit patient preferences", Int J Technol Assess Health Care, 27, pp.369~375 (2011)
10. Soczynska JK, "The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial", Psychiatry Res, 220, pp.245~250 (2014)
11. Mahableshwarkar AR, "A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder", Neuropsychopharmacology, 40, pp.2025~2037 (2015)
12. Rosenblat JD, "The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials", Int J Neuropsychopharmacol, 19, pp.pyv082~ (2015)
13. Keefe RS, "Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review", J Clin Psychiatry, 75, pp.864~876 (2014)
14. Elgamal S, "Clinical factors that predict cognitive function in patients with major depression", Can J Psychiatry, 55, pp.653~661 (2010)
15. Gu CZ, "Predictors of neurocognitive impairment at 2years after a first-episode major depressive disorder", Compr Psychiatry, 68, pp.24~33 (2016)
16. Evans VC, "The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review", J Clin Psychiatry, 75, pp.1359~1370 (2014)
17. Sheehan DV, "The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10", J Clin Psychiatry, 59(Suppl 20), pp.22~33 (1998)
18. 김재민, "Development of a Korean Version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 14(1), pp.26~32 (2016), 대한정신약물학회
19. Takasaki H, "Validity and reliability of the perceived deficit questionnaire to assess cognitive symptoms in people with chronic whip-lash-associated disorders", Arch Phys Med Rehabil, 93, pp.1774~1781 (2012)
20. McIntyre RS, "A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults", Int J Neuropsychopharmacol, 17, pp.1557~1567 (2014)
21. Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
22. Leon AC, "Assessing psychiatric impairment in primary care with the Sheehan disability scale", Int J Psychiatry Med, 27, pp.93~105 (1997)
23. EuroQol Group, "EuroQol--a new facility for the measurement of health-related quality of life", Health Policy, 16, pp.199~208 (1990)
24. Bose A, "Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine", Clin Drug Investig, 32, pp.373~385 (2012)
25. McDermott LM, "A meta-analysis of depression severity and cognitive function", J Affect Disord, 119, pp.1~8 (2009)
26. de Vries G, "Return to work after sick leave due to depression; a conceptual analysis based on perspectives of patients, supervisors and occupational physicians", J Affect Disord, 136, pp.1017~1026 (2012)
27. Blank L, "A systematic review of the factors which predict return to work for people suffering episodes of poor mental health", J Occup Rehabil, 18, pp.27~34 (2008)
28. Cai H, "Effect of exercise on cognitive function in chronic disease patients: a meta-analysis and systematic review of randomized controlled trials", Clin Interv Aging, 12, pp.773~783 (2017)
29. Kramer AF, "Exercise, cognition, and the aging brain", J Appl Physiol, 101, pp.1237~1242 (2006)
30. Barker MJ, "Cognitive effects of long-term benzodiazepine use: a meta-analysis", CNS Drugs, 18, pp.37~48 (2004)
31. Verster JC, "Effects of alprazolam on driving ability, memory functioning and psychomotor performance:a randomized, placebo-controlled study", Neuropsychopharmacology, 27, pp.260~269 (2002)
32. Yang SJ, "Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: the CRESCEND study", Psychiatry Res, 189, pp.82~90 (2011)
33. McIntyre RS, "Using measurement strategies to identify and monitor residual symptoms", J Clin Psychiatry, 74(Suppl 2), pp.14~18 (2013)
34. Raskin J, "Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial", Am J Psychiatry, 164, pp.900~909 (2007)

관련 논문AI추천